Vice President and Chief Scientific Officer (CSO)
Maurizio Ceppi joined Transgene in September 2024 as Vice President in charge of Research and Development (Chief Scientific Officer – CSO). With over 15 years in the oncology life sciences industry, he holds a deep expertise in cancer immunotherapy and precision medicine. Throughout his career, Maurizio Ceppi has played a pivotal role in the preclinical and clinical development of innovative therapies, including monoclonal and bispecific antibodies, small molecules, and mRNA vaccines. Dr. Ceppi brings a strong expertise in managing multidisciplinary teams, an expertise acquired at leading pharmaceutical and biotechnology companies such as Roche and iTeos Therapeutics, where he combined scientific leadership with strategic vision.
Maurizio Ceppi holds a PhD in Molecular Biology from the Department of Medicine of the University of Fribourg. He is an active contributor to the scientific community, with over 60 publications and holds eight patents.
